GlassScriptPhysician profile
Jason D Harrah
NPI 1043297419
$5,914.75
in general payments reported to CMS, 2019-2025
44 companies · $1,472 in 2025
The $1,472 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.79 · 2020: $503 · 2021: $846 · 2022: $679 · 2023: $979 · 2024: $1,395 · 2025: $1,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,845.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,287.08 | 2021-2025 | |
| Novo Nordisk INC | $843.72 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $340.00 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $302.21 | 2019-2025 | |
| Amgen INC. | $233.83 | 2020-2025 | Repatha, Otezla, Krystexxa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225.92 | 2024-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $212.52 | 2019-2025 | Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $183.51 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $182.62 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $171.53 | 2019-2021 | |
| Amarin Pharma, INC. | $157.20 | 2020-2021 | |
| Lundbeck LLC | $141.83 | 2023-2024 | Vyepti, Rexulti |
| Abbott Laboratories | $130.71 | 2021-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $128.57 | 2020-2023 | Veozah |
| Exact Sciences Corporation | $121.45 | 2023-2025 | Cologuard Collection Kit |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Harrah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.